{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:07:19Z","timestamp":1788286039628,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00259-026-07763-z","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T02:36:15Z","timestamp":1769567775000},"page":"3542-3551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multidisciplinary team interpretation performance for indeterminate bone uptake on PSMA PET during prostate cancer staging: Comparison with PROMISE criteria"],"prefix":"10.1007","volume":"53","author":[{"given":"Dimitrios","family":"Priftakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadilah","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noora","family":"Bin Essa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Davda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lyasheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeshna","family":"Maitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fraioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamshed","family":"Bomanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Afaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"10231","key":"7763_CR1","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208\u201316.","journal-title":"Lancet"},{"issue":"1","key":"7763_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"KM Chow","year":"2023","unstructured":"Chow KM, So WZ, Lee HJ, et al. Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate- to high-risk prostate cancer: a systematic review and meta-analysis. Eur Urol. 2023;84(1):36\u201348.","journal-title":"Eur Urol"},{"issue":"15","key":"7763_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025417","volume":"100","author":"R Zhao","year":"2021","unstructured":"Zhao R, Li Y, Nie L, Qin K, Zhang H, Shi H. The meta-analysis of the effect of 68Ga-PSMA-PET\/CT diagnosis of prostatic cancer compared with bone scan. Medicine. 2021;100(15):e25417.","journal-title":"Medicine"},{"issue":"suppl 1","key":"7763_CR4","volume":"61","author":"A Afaq","year":"2020","unstructured":"Afaq A, Young M, Priftakis D, Kayani I, Bomanji J. Assessment of benign bone marrow uptake with 18F-PSMA-1007 in prostate cancer using PET\/MRI. J Nucl Med. 2020;61(suppl 1):1255.","journal-title":"J Nucl Med"},{"issue":"1","key":"7763_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2967\/jnumed.119.229187","volume":"61","author":"I \u200cRauscher","year":"2020","unstructured":"\u200cRauscher I, Kr\u00f6nke M, K\u00f6nig M, et al. Matched-pair comparison of 68Ga-PSMA-11 and 18F-PSMA-1007 PET\/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. J Nucl Med. 2020;61(1):51\u20137.","journal-title":"J Nucl Med"},{"issue":"3","key":"7763_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2967\/jnumed.122.264334","volume":"64","author":"TE Phelps","year":"2023","unstructured":"Phelps TE, Harmon SA, Mena E, et al. Predicting outcomes of indeterminate bone lesions on 18F-DCFPyL PSMA PET\/CT scans in the setting of High-Risk primary or recurrent prostate cancer. J Nucl Med. 2023;64(3):395\u2013401.","journal-title":"J Nucl Med"},{"issue":"11","key":"7763_CR7","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1007\/s00259-022-05745-5","volume":"49","author":"B Vollnberg","year":"2022","unstructured":"Vollnberg B, Alberts I, Genitsch V, Rominger A, Afshar-Oromieh A. Assessment of malignancy and PSMA expression of uncertain bone foci in [18F]PSMA-1007 PET\/CT for prostate cancer\u2014a single-centre experience of PET-guided biopsies. Eur J Nucl Med Mol Imaging. 2022;49(11):3910\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7763_CR8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed MiTNM classification for the interpretation of PSMA-Ligand PET\/CT. J Nucl Med. 2018;59(3):469\u201378.","journal-title":"J Nucl Med"},{"issue":"5","key":"7763_CR9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.eururo.2023.06.008","volume":"84","author":"RA Werner","year":"2023","unstructured":"Werner RA, Hartrampf PE, Fendler WP, et al. Prostate-specific membrane antigen reporting and data system version 2.0. Eur Urol. 2023;84(5):491\u2013502.","journal-title":"Eur Urol"},{"key":"7763_CR10","doi-asserted-by":"publisher","unstructured":"Kuten J, Dekalo S, Mintz I, Yossepowitch O, Mano R, Even-Sapir E. The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0. EJNMMI Res. 2021. https:\/\/doi.org\/10.1186\/s13550-020-00745-8.","DOI":"10.1186\/s13550-020-00745-8"},{"key":"7763_CR11","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","volume":"48","author":"F Ceci","year":"2021","unstructured":"Ceci F, Oprea-Lager DE, Emmett L, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48:1626\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"7763_CR12","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1007\/s00259-021-05424-x","volume":"48","author":"H Gr\u00fcnig","year":"2021","unstructured":"Gr\u00fcnig H, Maurer A, Thali Y, et al. Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. Eur J Nucl Med Mol Imaging. 2021;48(13):4483\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"7763_CR13","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1007\/s00259-021-05456-3","volume":"48","author":"EG Arnfield","year":"2021","unstructured":"Arnfield EG, Thomas PA, Roberts MJ, et al. Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation. Eur J Nucl Med Mol Imaging. 2021;48(13):4495\u2013507.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"7763_CR14","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1007\/s00259-024-06797-5","volume":"51","author":"A Rizzo","year":"2024","unstructured":"Rizzo A, Morbelli S, Albano D, et al. The homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition. Eur J Nucl Med Mol Imaging. 2024;51(12):3753\u201364.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7763_CR15","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/bju.15152","volume":"126","author":"MY Chen","year":"2020","unstructured":"Chen MY, Franklin A, Yaxley J, et al. Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre\u2010treatment staging <Superscript>68<\/Superscript>Ga\u2010PSMA\u201011 positron emission tomography scans for men with prostate cancer: benign or malignant? BJU Int. 2020;126(3):396\u2013401.","journal-title":"BJU Int"},{"issue":"10","key":"7763_CR16","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.3390\/diagnostics13101730","volume":"13","author":"F Gossili","year":"2023","unstructured":"Gossili F, Lyngby CG, L\u00f8gager V, Zacho HD. Intense PSMA uptake in a vertebral hemangioma mimicking a solitary bone metastasis in the primary staging of prostate cancer via 68Ga-PSMA PET\/CT. Diagnostics. 2023;13(10):1730.","journal-title":"Diagnostics"},{"key":"7763_CR17","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","volume":"25","author":"MJ \u200cKarpinski","year":"2024","unstructured":"\u200cKarpinski MJ, H\u00fcsing J, Claassen K, et al. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. Lancet Oncol. 2024;25:1188\u2013201.","journal-title":"Lancet Oncol"},{"issue":"1","key":"7763_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ctrv.2013.07.001","volume":"40","author":"A Briganti","year":"2014","unstructured":"Briganti A, Suardi N, Gallina A, et al. Predicting the risk of bone metastasis in prostate cancer. Cancer Treat Rev. 2014;40(1):3\u201311.","journal-title":"Cancer Treat Rev"},{"key":"7763_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.euros.2023.12.001","volume":"59","author":"WI \u200cLuining","year":"2024","unstructured":"\u200cLuining WI, Hagens MJ, Meijer D, et al. The probability of metastases within different prostate-specific antigen ranges using prostate-specific membrane antigen positron emission tomography in patients with newly diagnosed prostate cancer. Eur Urol Open Sci. 2024;59:55\u201362.","journal-title":"Eur Urol Open Sci"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07763-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07763-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07763-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:25:53Z","timestamp":1777274753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07763-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7763"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07763-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was granted by Health Research Authority and Health and Care Research Wales (HRA\/HCRW). Integrated Research Application System (IRAS) project ID: 265180.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study for use and publication of their anonymised data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}